NDAINJECTIONINJECTABLE
Approved
Aug 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfadiazine sodium is an injectable sulfonamide antibiotic approved in 1941 for treatment of bacterial infections, particularly toxoplasmosis and certain streptococcal infections. It works by inhibiting bacterial dihydrofolate reductase, disrupting folate synthesis and nucleotide production. This legacy antibiotic remains in use for serious infections where oral alternatives are not feasible.
LOE Approaching
Approaching loss of exclusivity signals declining market opportunity; brand team likely focused on cost management and niche positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on sulfadiazine sodium offers limited career growth opportunities given its LOE-approaching lifecycle and minimal linked job openings. Roles focus on defensive commercial strategies, cost management, and niche market maintenance rather than innovation or expansion.
Medical Science LiaisonBrand Manager
Worked on SULFADIAZINE SODIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.